Home > Press > Mersana Therapeutics, Inc. Appoints John H. van Duzer, Ph.D., as Vice President of Manufacturing and Pharmaceutical Sciences
Mersana, a cancer therapeutics company, announced today that John H. van Duzer, Ph.D. has joined the company as Vice President of Manufacturing & Pharmaceutical Sciences.
Mersana Therapeutics, Inc. Appoints John H. van Duzer, Ph.D., as Vice President of Manufacturing and Pharmaceutical Sciences
CAMBRIDGE, MA | Posted on January 16th, 2008
"John van Duzer adds a critical component to the Mersana management team with his manufacturing and development experience," said Julie A. Olson, Ph.D., President and CEO at Mersana. "As a clinical development-stage company, manufacturing plays a key role in the advancement of our products and John's contributions will impact our entire pipeline. We are also fortunate that John's early experience in research enables the seamless transition of candidates from research into development."
Dr. van Duzer has over eighteen years of experience in pharmaceutical R&D. As a Vice President of Manufacturing at ActivBiotics, he led efforts for the development of a liquid dosage form of a rifamycin, an oral antibacterial agent. Prior to joining ActivBiotics, Dr. van Duzer served as the Director of Chemistry at Inotek Corporation, a clinical-stage, drug development company. Prior to joining Inotek, Dr. van Duzer worked as a medicinal chemist in the research group of Ciba-Geigy and subsequently Novartis for twelve years. Most notable is his invention of lumiracoxib, a COX-2 inhibitor currently sold in a number of countries. He is a co-author of over a dozen scientific publications and is an inventor on numerous US and international patents. He received his BA in Chemistry from the University of Pennsylvania and his Ph.D. in Organic Chemistry from Yale University.
About Mersana Therapeutics, Inc.
Mersana, a privately held, venture backed company, utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. The key component of Mersana's platform is Fleximer(R), a novel, biodegradable and bio-inert polymer that can be chemically linked to small molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer- camptothecin conjugate which is currently in Phase 1 clinical trials, and several preclinical oncology compounds. Mersana's investors include Fidelity Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech Ventures.
Fleximer(R) is a trademark of Mersana Therapeutics, Inc.
For more information, please click here
Mersana Therapeutics, Inc.
840 Memorial Drive
Cambridge, MA 02139
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
News and information
East China University of Science and Technology Purchases Nanonex Advanced Nanoimprint Tool NX-B200 July 30th, 2014
Watching Schrödinger's cat die (or come to life): Steering quantum evolution & using probes to conduct continuous error correction in quantum computers July 30th, 2014
From Narrow to Broad July 30th, 2014
FLAG-ERA and TNT2014 join efforts: Graphene Networking at its higher level in Barcelona: Encourage the participation in a joint transnational call July 30th, 2014
New imaging agent provides better picture of the gut July 30th, 2014
Zenosense, Inc. July 29th, 2014
Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014
FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014
University of Manchester selects Anasys AFM-IR for coatings and corrosion research July 30th, 2014
Nature inspires a greener way to make colorful plastics July 30th, 2014
Analytical solutions from Malvern Instruments support University of Wisconsin-Milwaukee researchers in understanding environmental effects of nanomaterials July 30th, 2014
FEI Unveils New Solutions for Faster Time-to-Analysis in Metals Research July 30th, 2014
ACS Biomaterials Science & Engineering™: Brand-new journal names editor July 29th, 2014
Organometallics welcomes new editor-in-chief: Paul Chirik, Ph.D. July 22nd, 2014
NSS Pays Tribute to Space Pioneer Frederick I. Ordway III July 7th, 2014
Harris & Harris Group Announces Changes to Its Legal Department June 9th, 2014